Beyond Air Inc
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treat… Read more
Beyond Air Inc (XAIR) - Net Assets
Latest net assets as of December 2025: $8.29 Million USD
Based on the latest financial reports, Beyond Air Inc (XAIR) has net assets worth $8.29 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($36.77 Million) and total liabilities ($28.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.29 Million |
| % of Total Assets | 22.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | -52.92% |
| 10-Year Change | N/A |
| Growth Volatility | 136.43 |
Beyond Air Inc - Net Assets Trend (2014–2025)
This chart illustrates how Beyond Air Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beyond Air Inc (2014–2025)
The table below shows the annual net assets of Beyond Air Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $14.34 Million | -47.25% |
| 2024-03-31 | $27.19 Million | -35.31% |
| 2023-03-31 | $42.03 Million | -46.26% |
| 2022-03-31 | $78.21 Million | +156.73% |
| 2021-03-31 | $30.46 Million | +68.37% |
| 2020-03-31 | $18.09 Million | +349.52% |
| 2019-03-31 | $4.02 Million | +160.64% |
| 2018-03-31 | $1.54 Million | +6237.52% |
| 2017-03-31 | $-25.16K | 0.00% |
| 2016-03-31 | $-25.16K | +97.67% |
| 2015-03-31 | $-1.08 Million | -365.52% |
| 2014-03-31 | $-232.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beyond Air Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28457300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.06% |
| Other Comprehensive Income | $-60.00K | -0.44% |
| Other Components | $299.96 Million | 2208.33% |
| Total Equity | $13.58 Million | 100.00% |
Beyond Air Inc Competitors by Market Cap
The table below lists competitors of Beyond Air Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elgi Rubber Company Limited
NSE:ELGIRUBCO
|
$7.58 Million |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
$7.58 Million |
|
Xbrane Biopharma AB
ST:XBRANE
|
$7.58 Million |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
$7.58 Million |
|
Iconic Worldwide Bhd
KLSE:9113
|
$7.58 Million |
|
Turnium Technology Group Inc.
V:TTGI
|
$7.57 Million |
|
Nam Sung
KO:004270
|
$7.57 Million |
|
KRONA PUBLIC REAL ESTATE
F:927
|
$7.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beyond Air Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,048,000 to 13,583,000, a change of -11,465,000 (-45.8%).
- Net loss of 46,625,000 reduced equity.
- New share issuances of 23,009,000 increased equity.
- Other comprehensive income decreased equity by 45,000.
- Other factors increased equity by 12,196,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-46.62 Million | -343.26% |
| Share Issuances | $23.01 Million | +169.4% |
| Other Comprehensive Income | $-45.00K | -0.33% |
| Other Changes | $12.20 Million | +89.79% |
| Total Change | $- | -45.77% |
Book Value vs Market Value Analysis
This analysis compares Beyond Air Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-03-31 | $-0.08 | $0.81 | x |
| 2015-03-31 | $-0.37 | $0.81 | x |
| 2016-03-31 | $-0.02 | $0.81 | x |
| 2017-03-31 | $-0.24 | $0.81 | x |
| 2018-03-31 | $5.15 | $0.81 | x |
| 2019-03-31 | $9.47 | $0.81 | x |
| 2020-03-31 | $31.45 | $0.81 | x |
| 2021-03-31 | $33.84 | $0.81 | x |
| 2022-03-31 | $2.83 | $0.81 | x |
| 2023-03-31 | $1.26 | $0.81 | x |
| 2024-03-31 | $15.11 | $0.81 | x |
| 2025-03-31 | $4.01 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beyond Air Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -343.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1258.43%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 2.21x
- Recent ROE (-343.26%) is below the historical average (-192.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.62 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.70 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.66 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.23K |
| 2018 | -1168.50% | 0.00% | 0.00x | 6.06x | $-18.20 Million |
| 2019 | -162.95% | -84.91% | 0.82x | 2.34x | $-6.96 Million |
| 2020 | -110.23% | -1434.61% | 0.05x | 1.52x | $-21.75 Million |
| 2021 | -75.09% | -2620.27% | 0.02x | 1.33x | $-25.92 Million |
| 2022 | -59.39% | -29738.27% | 0.00x | 1.36x | $-50.45 Million |
| 2023 | -147.21% | -94603.39% | 0.00x | 1.81x | $-59.61 Million |
| 2024 | -240.51% | -5197.76% | 0.02x | 2.27x | $-62.75 Million |
| 2025 | -343.26% | -1258.43% | 0.12x | 2.21x | $-47.98 Million |
Industry Comparison
This section compares Beyond Air Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beyond Air Inc (XAIR) | $8.29 Million | 0.00% | 3.44x | $7.58 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |